Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (131-140 of 161) with videos related to

Pageof 17
Sort By:
Journal of Gastroenterology and Hepatology|August 12, 2016
Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patientsKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
The Journal of Infection|December 26, 2021
Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibodyHaruna Hatooka, Yumi Shimomura, Michio Imamura, et al.
Antiviral Therapy|September 22, 2017
The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patientsMio Kurihara, Masataka Tsuge, Eisuke Murakami, et al.
Journal of Gastroenterology and Hepatology|July 21, 2023
Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failureSerami Murakami, Takuro Uchida, Michio Imamura, et al.
Gut|January 17, 2013
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric miceNiu Shi, Nobuhiko Hiraga, Michio Imamura, et al.
Journal of Viral Hepatitis|June 9, 2021
Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patientsYuno Nishida, Michio Imamura, Yuji Teraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2026
Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular CarcinomaRyoichi Miura, Tomokazu Kawaoka, Saki Sueda, et al.
Biochemical and Biophysical Research Communications|May 1, 2021
Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted miceKazuki Ohya, Michio Imamura, Yuji Teraoka, et al.
The Journal of General Virology|June 15, 2019
Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized miceMitsutaka Osawa, Takuro Uchida, Michio Imamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 3, 2014
Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis CYuko Nagaoki, Michio Imamura, Yoshiiku Kawakami, et al.
Pageof 17

Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
Journal of Gastroenterology and Hepatology|August 12, 2016
Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patientsKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
The Journal of Infection|December 26, 2021
Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibodyHaruna Hatooka, Yumi Shimomura, Michio Imamura, et al.
Antiviral Therapy|September 22, 2017
The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patientsMio Kurihara, Masataka Tsuge, Eisuke Murakami, et al.
Journal of Gastroenterology and Hepatology|July 21, 2023
Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failureSerami Murakami, Takuro Uchida, Michio Imamura, et al.
Gut|January 17, 2013
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric miceNiu Shi, Nobuhiko Hiraga, Michio Imamura, et al.
Journal of Viral Hepatitis|June 9, 2021
Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patientsYuno Nishida, Michio Imamura, Yuji Teraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2026
Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular CarcinomaRyoichi Miura, Tomokazu Kawaoka, Saki Sueda, et al.
Biochemical and Biophysical Research Communications|May 1, 2021
Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted miceKazuki Ohya, Michio Imamura, Yuji Teraoka, et al.
The Journal of General Virology|June 15, 2019
Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized miceMitsutaka Osawa, Takuro Uchida, Michio Imamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 3, 2014
Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis CYuko Nagaoki, Michio Imamura, Yoshiiku Kawakami, et al.
Pageof 17